Dr. Paul A. Hellstern, M.D.
Gastroenterology (Gastroenterology Physician)
- Medicare participating
At a glance
- Medical school
- Wright State University Boonshoft School of Medicine (1990)
- Years since graduation
- 36
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 1,171
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1990Medical school: Wright State University Boonshoft School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Gastroenterology Physician primary
FL license ME0068219
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- HCA Florida Citrus Hospital Inverness, FL
- Tampa General Hospital Crystal River Crystal River, FL
Medical groups
- Bikkasani Ram Hellstern and Chandrupatla MDpa (12 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 1,171
- Services billed
- 4,789
- Patients’ average age
- 76
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 20-29 minutes | 1,097 | 651 |
| Pathology examination of tissue using a microscope, intermediate complexity | 704 | 367 |
| Special stained specimen slides to examine tissue including interpretation and report | 247 | 161 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 205 | 197 |
| New patient office or other outpatient visit, 30-44 minutes | 192 | 192 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 186 | 106 |
| Special stained specimen slides to identify organisms including interpretation and report | 156 | 107 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 155 | 151 |
| Microscopic genetic analysis of tumor, manual | 144 | 101 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 120 | 118 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Pantoprazole Sodium Other prescribers in Crystal River, FL | 808 |
| Omeprazole Other prescribers in Crystal River, FL | 592 |
| Clenpiq (sod picosulf/mag ox/citric ac) | 433 |
| Famotidine Other prescribers in Crystal River, FL | 380 |
| Dicyclomine Hcl Other prescribers in Crystal River, FL | 292 |
| Colestipol Hcl Other prescribers in Crystal River, FL | 122 |
| Metoclopramide Hcl Other prescribers in Crystal River, FL | 97 |
| Prednisone Other prescribers in Crystal River, FL | 79 |
| Sucralfate Other prescribers in Crystal River, FL | 64 |
| Gavilyte-C (peg3350/sod sulf,bicarb,cl/kcl) Other prescribers in Crystal River, FL | 57 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 5 companies reported 14 payments worth $239 in total to this clinician.
| AbbVie Inc. | $166 |
|---|---|
| Genzyme Corporation | $25.85 |
| Galderma Laboratories, L.P. | $21.99 |
| Stryker Corporation | $14.29 |
| Phathom Pharmaceuticals, Inc. | $10.57 |
| Food and Beverage | $239 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 25 industry-funded studies in 2025, from 10 companies. The companies reported $489,752 in research payments for these studies, mostly to the institutions running them.
- Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
AbbVie Inc. · Recruiting · NCT06548542 - A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease
AbbVie Inc. · Active, not recruiting · NCT03105102 - M24-885 - Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD)
AbbVie Inc. - A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2a Trial to Characterize the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease While Undergoing Oral Gluten Exposure
Teva Pharmaceuticals USA, Inc. - A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)
Madrigal Pharmaceuticals · Active, not recruiting · NCT04951219 - A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis
Madrigal Pharmaceuticals · Active, not recruiting · NCT03900429 - A Phase 2b/3 Randomized, Double-blind, Placebo-Controlled, Parallel Group, Multicenter Protocol to Evaluate the Efficacy and Safety of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
Janssen Research & Development, LLC - A Phase 3 Randomized, Double-blind, Placebo-Controlled, Parallel Group, Multicenter Protocol in Adults with an Open Label Study in Adolescents to Evaluate the Efficacy and Safety of Induction and Maintenance Therapy…
Janssen Research & Development, LLC - A study of TAK-062 in treatment of active celiac disease in participants attempting a gluten-free diet
Takeda Pharmaceuticals U.S.A., Inc. - Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presume…
Boehringer Ingelheim International GmbH
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.